CPRC
-
February 18, 2022
Olaparib Shows Promise for Castrate-Resistant Prostate Cancer Bookmark
George Lundberg, MDThis Business Wire press release announces results from a clinical trial indicating that adding the drug olaparib (brand name Lynparza) to treatment for castrate-resistant prostate cancer enhanced disease-free progression, regardless of biomarker status.
.